当前位置：
X-MOL 学术
›
Eur. J. Neurol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
European Journal of Neurology ( IF 4.5 ) Pub Date : 2020-12-28 , DOI: 10.1111/ene.14705 Gabriel Bsteh 1 , Harald Hegen 2 , Katharina Riedl 1 , Patrick Altmann 1 , Michael Auer 2 , Klaus Berek 2 , Franziska Di Pauli 2 , Rainer Ehling 3 , Barbara Kornek 1 , Tobias Monschein 1 , Walter Rinner 1 , Christiane Schmied 1 , Sebastian Wurth 4 , Karin Zebenholzer 1 , Anne Zinganell 2 , Tobias Zrzavy 1 , Gudrun Zulehner 1 , Florian Deisenhammer 2 , Paulus Rommer 1 , Fritz Leutmezer 1 , Thomas Berger 1
European Journal of Neurology ( IF 4.5 ) Pub Date : 2020-12-28 , DOI: 10.1111/ene.14705 Gabriel Bsteh 1 , Harald Hegen 2 , Katharina Riedl 1 , Patrick Altmann 1 , Michael Auer 2 , Klaus Berek 2 , Franziska Di Pauli 2 , Rainer Ehling 3 , Barbara Kornek 1 , Tobias Monschein 1 , Walter Rinner 1 , Christiane Schmied 1 , Sebastian Wurth 4 , Karin Zebenholzer 1 , Anne Zinganell 2 , Tobias Zrzavy 1 , Gudrun Zulehner 1 , Florian Deisenhammer 2 , Paulus Rommer 1 , Fritz Leutmezer 1 , Thomas Berger 1
Affiliation
|
There is a lack of evidence guiding discontinuation of disease‐modifying therapy (DMT) in relapsing multiple sclerosis (RMS). Thus, the objective of this study was to generate and validate a risk score for disease reactivation after DMT discontinuation in RMS.
中文翻译：
量化多发性硬化症患者停用干扰素和醋酸格拉替雷后疾病再激活的风险：VIAADISC 评分
缺乏证据指导在复发性多发性硬化症 (RMS) 中停止疾病缓解治疗 (DMT)。因此，本研究的目的是生成和验证 RMS 中 DMT 中断后疾病再激活的风险评分。
更新日期：2020-12-28
中文翻译：
量化多发性硬化症患者停用干扰素和醋酸格拉替雷后疾病再激活的风险：VIAADISC 评分
缺乏证据指导在复发性多发性硬化症 (RMS) 中停止疾病缓解治疗 (DMT)。因此，本研究的目的是生成和验证 RMS 中 DMT 中断后疾病再激活的风险评分。
京公网安备 11010802027423号